Literature DB >> 11122839

Hodgkin's disease: prognostic factors and short-course regimens.

N L Bartlett1, S M Arackal.   

Abstract

Both topics discussed in this review, prognostic factors and short-course regimens for Hodgkin's disease, have been the focus of recent research with the goal of developing tools and treatments that will result in the highest cure rates with the least long-term sequelae. A new "prognostic score" for advanced-stage Hodgkin's disease and several potential prognostic factors, including soluble CD30, soluble interleukin-2 receptor, activated cytotoxic T-lymphocytes, and Epstein-Barr virus, are discussed. Preliminary reports of short-course chemotherapy regimens with and without radiotherapy for all stages of Hodgkin's disease are summarized.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122839     DOI： 10.1007/s11912-000-0089-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


  31 in total

1.  Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease.

Authors:  P G Murray; L J Billingham; H T Hassan; J R Flavell; P N Nelson; K Scott; G Reynolds; C M Constandinou; D J Kerr; E C Devey; J Crocker; L S Young
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

2.  Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.

Authors:  P Colonna; J P Jais; B Desablens; J L Harousseau; J Brière; M Boasson; A Lemevel; P Casassus; P Y Le Prisé; F Guilhot; C Ghandour; F Lejeune; J M Andrieu
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

3.  Prognostic factors in advanced Hodgkin's disease--can they guide therapeutic decisions?

Authors:  P Brice
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

4.  Hodgkin's disease: complications of therapy and excess mortality.

Authors:  R T Hoppe
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

5.  Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse.

Authors:  C Beham-Schmid; K H Heider; G Hoefler; K Zatloukal
Journal:  J Pathol       Date:  1998-12       Impact factor: 7.996

6.  Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease.

Authors:  S Pavlovsky; E Schvartzman; F Lastiri; H Magnasco; C Corrado; E Raslawski; M E Cancela; M C Ardaiz; I Cerutti; A Rosso; S Bruno; P N Aranguren; A Salvarezza; H Donato; E Dibar; S Zirone
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

7.  Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051).

Authors:  T H Wasserman; G R Petroni; F E Millard; C T Chung; M Barcos; J L Johnson; G P Canellos; B A Peterson
Journal:  Cancer       Date:  1999-10-15       Impact factor: 6.860

8.  Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival.

Authors:  A H Sarris; K O Kliche; P Pethambaram; A Preti; S Tucker; C Jackow; O Messina; W Pugh; F B Hagemeister; P McLaughlin; M A Rodriguez; J Romaguera; H Fritsche; T Witzig; M Duvic; M Andreeff; F Cabanillas
Journal:  Ann Oncol       Date:  1999-04       Impact factor: 32.976

9.  Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.

Authors:  S Viviani; E Camerini; V Bonfante; A Santoro; M Balzarotti; M Fornier; L Devizzi; P Verderio; P Valagussa; G Bonadonna
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.

Authors:  P Brice; Y Bastion; M Divine; G Nedellec; A Ferrant; J Gabarre; O Reman; E Lepage; C Fermé
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.